SlideShare une entreprise Scribd logo
1  sur  13
PCR Detection of Virulence Factors in
Escherichia coli from
Diabetic and Non-Diabetic Patients
with Urinary Tract Infections
in Tripoli-Libya
Khalifa Sifaw Ghenghesh, Einass El-Kateb,
Nuri Berbash, Rania Abdel-Khalek,
Salwa F. Ahmed, John D. Klena
Faculty of Medicine, Tripoli University;
Faculty of Sciences; Tripoli University, Tripoli, Libya and
US Naval Medical Research Unit#3, Cairo, Egypt.
Introduction
• Uropathogenic Escherichia coli (UPEC) is the most
common cause of urinary tract infections (UTIs) in
humans.
• UPEC colonization of the UT is made possible by several
virulence factors (VF):
–
–
–
–
–

fimbrial adhesins >> e.g. type-1 fimbriae >> adherence
nonfimbrial adhesins >> adherence
sidrophores >> iron-acquisition systems
secreted toxins >> hemolysin
cytotoxic necrotizing factor 1 >> acts on epithelial or endothelial

cells, or monocyte-macrophages via
activation of GTP-binding proteins

– capsule-forming polysaccharides >> immune evasion
Introduction
• Phylogenetic groups of E. coli strains:
– Groups A and B1 >> commensal strains.
– Groups B2 and D >> mainly associated with E. coli
strains causing extraintestinal infections.
– Most VFs-containing UPECs cluster mainly either in
phylogeny group B2 or shared within groups B2 and
D

• Fluoroquinolones (e.g. ciprofloxacin):
– Drugs of choice in empirical treatment of
uncomplicated UTI.
– Studies have shown that resistance of UPEC to
ciprofloxacin and to may be associated with
decreased expression or loss of some virulence
factors
Introduction
• In developed countries:
– Several investigators have reported that infections
including UTIs are more frequently reported among
diabetic patients than the general population, while
others found no such difference.
– Studies have shown that hosts with predisposing
factors, such as diabetes, can acquire UTIs caused
by less virulent E. coli strains.

• In developing countries.
– Lack of information on the phylogenetic grouping
and virulence factors of UPEC from diabetic and
non-diabetic patients.
Objectives of the Study
• To determine the phylogenetic grouping and
the virulence factors of UPEC isolated from
diabetic and non-diabetic patients in Tripoli,
Libya using PCR techniques.
Methods
• Using multiplex PCR
– 48 E. coli isolates from Libyan patients with UTIs:
• 19 from diabetics and 29 from non-diabetics
• Examined for the presence of genetic determinants of
19 extraintestinal virulence factors.
• The primer pairs for the 19 virulence genes and
amplification conditions have been described
previously (Johnson & Stell 2000).
• Examined for phylogenetic grouping (A, B1, B2, or D) as
previously reported (Clermont et al., 2000).
• Reactions were performed in a GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA, USA).
• DNA sequencing was used to confirm the identity of
amplified PCR products and establish positive controls.
PCR detection of virulence genes in UPEC
Results
• Of the virulence genes examined, 3 or more
were found in 37.5% of E. coli studied.
• Only genes fimH (coding for type 1 fimbriae)
and traT (coding for serum resistance) were
both found significantly more common in E.
coli from non-diabetic than in diabetic patients
(P<0.02, OR=7.88 and P<0.00007, OR=14.38,
respectively).
• several of the VFs detected in the present study
were not reported previously in E. coli isolates
from diabetics with UTI and these include fyuA,
kpsMT II, and traT.
Table 1. Distribution of virulence factors (VF) among uropathogenic
Escherichia coli isolated from diabetics and non-diabetics
VF

No (%) of associated VF
Diabetics
Non-diabetics
(n=19)
(n=29)

--------------------------------------------------------------------------------------------------------------------------------------papA (P fimbriae)
0 (0.0)
0 (0.0)
papC (P fimbriae)
1 (5)
3 (10)
papEF (P fimbriae)
1 (5)
3 (10)
sfa/focD (Dr family adhesions)
2 (11)
8 (28)
focG (F1C fimbriae)
1 (5)
7 (24)
afa/draBC (Dr family adhesions)
0 (0.0)
4 (14)
bmaE (M fimbirae)
0 (0.0)
0 (0.0)
nfaE (Nonfimbrial adhesion-1)
0 (0.0)
0 (0.0)
fimH (Type 1 fimbriae)
12 (63)
27 (93)*
hylA (hemolysin)
4 (21)
7 (24)
fyuA (Yersiniabactin)
12 (63)
11 (38)
iutA (Aerobactin)
13 (68)
21 (72)
kpsMT II (Capsule synthesis group II)
7 (37)
11 (38)
kpsMT III (Capsule synthesis group III)
0 (0.0)
0 (0.0)
rfc (O4 LPS)
0 (0.0)
0 (0.0)
ibeA (Invasion)
0 (0.0)
1 (4)
cvaC (Colicin V)
0 (0.0)
1 (4)
traT (Serum resistance)
4 (21)
23 (79)*
PAI (Pathogenicity-associated island)
0 (0.0)
2 (7)
Multivirulent (>3 genes)
11 (58)
25 (86)*
Table 2. Distribution of virulence factors (VF) among uropathogenic Escherichia coli
isolated from diabetics and non-diabetics in relation to ciprofloxacin resistance

VF

No (%) of associated VF
Cipro-susceptible
Cipro-resistant
(n=38)
(n=10)

------------------------------------------------------------------------------------------------------------------------------------------papA (P fimbriae)
0 (0.0)
0 (0.0)
papC (P fimbriae)
4 (11)
0 (0.0)
papEF (P fimbriae)
4 (11)
0 (0.0)
sfa/focD (Dr family adhesions)
10 (26)
0 (0.0)
focG (F1C fimbriae)
8 (21)
0 (0.0)
afa/draBC (Dr family adhesions)
4 (11)
0 (0.0)
bmaE (M fimbirae)
0 (0.0)
0 (0.0)
nfaE (Nonfimbrial adhesion-1)
0 (0.0)
0 (0.0)
fimH (Type 1 fimbriae)
32 (84)*
4 (40)
hylA (hemolysin)
11 (29)*
0 (0.0)
fyuA (Yersiniabactin)
19 (50)
4 (40)
iutA (Aerobactin)
28 (74)*
4 (40)
kpsMT II (Capsule synthesis group II)
18 (47)*
0 (0.0)
kpsMT III (Capsule synthesis group III)
0 (0.0)
0 (0.0)
rfc (O4 LPS)
0 (0.0)
0 (0.0)
ibeA (Invasion)
1 (3)
0 (0.0)
cvaC (Colicin V)
1 (3)
0 (0.0)
traT (Serum resistance)
23 (61)
4 (40)
PAI (Pathogenicity-associated island)
1 (3)
1 (10)
Multivirulent (>3 genes)
34 (90)*
2 (20)
Phylogeny groups among UPEC isolated from diabetics and
non-diabetics and in relation to ciprofloxacin resistance
Non
Phlyogeny

Diabetics

diabetics

Ciprosusceptible

Ciproresistant

group
(n=19)
(n=29)
(n=38)
(n=10)
---------------------------------------------------------------------------------------------------------------------

A
B1
B2
D

14 (74)1
0 (0.0)
3 (16)
2 (11)

4 (14)
1 (3.4)
8 (28)
16 (55)3

10 (26)
1 (3)
10 (26)
17 (45)4

8 (80)2
0 (0.0)
1 (10)
1 (10)
Results
• E. coli from diabetics is significantly statistically
associated with phylogeny group A than E. coli from
non-diabetics (P<0.00003, OR=17.50).
• E. coli from non-diabetics is significantly statistically
associated with phylogeny group D than E. coli from
diabetics (P<0.002, OR=10.46).
• Ciprofloxacin-resistant E. coli is significantly
statistically associated with phylogeny group A than
ciprofloxacin-susceptible E. coli (P<0.002, OR=11.20).
• Ciprofloxacin-susceptible E. coli is significantly
statistically associated with phylogeny group D than
ciprofloxacin-resistant E. coli (P<0.05, OR=7.29).
Conclusion
• In developing countries, UPEC causing UTIs in
diabetics are less virulent than UPEC causing UTIs
in non-diabetics which confirms the findings of
previously published studies from developed
countries.
• Studies are needed on the prevalence of VFs and
phylogenetic groups in UPEC from diabetic patients
in developing areas.
• These studies are important in understanding the
roles of these factors in causing UTI in diabetics as
well as in non-diabetics, which in turn may lead to
development of universal vaccines to prevent such
infections.

Contenu connexe

Tendances

Effect of a specific combination of mannan oligosaccharides and β-glucans ext...
Effect of a specific combination of mannan oligosaccharides and β-glucans ext...Effect of a specific combination of mannan oligosaccharides and β-glucans ext...
Effect of a specific combination of mannan oligosaccharides and β-glucans ext...Kawkab Abd El Aziz
 
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...eilosei
 
Detection of genetically modified soya, maize, and rice in vegetarian and hea...
Detection of genetically modified soya, maize, and rice in vegetarian and hea...Detection of genetically modified soya, maize, and rice in vegetarian and hea...
Detection of genetically modified soya, maize, and rice in vegetarian and hea...Gordana Zdjelar
 
Celltrion Healthcare Pipeline
Celltrion Healthcare PipelineCelltrion Healthcare Pipeline
Celltrion Healthcare Pipelinecelltrionh
 

Tendances (8)

cancerres
cancerrescancerres
cancerres
 
Effect of a specific combination of mannan oligosaccharides and β-glucans ext...
Effect of a specific combination of mannan oligosaccharides and β-glucans ext...Effect of a specific combination of mannan oligosaccharides and β-glucans ext...
Effect of a specific combination of mannan oligosaccharides and β-glucans ext...
 
Prieditis steatosis bcr10
Prieditis steatosis bcr10Prieditis steatosis bcr10
Prieditis steatosis bcr10
 
5. ramzy et al-2018-iubmb_life
5. ramzy et al-2018-iubmb_life5. ramzy et al-2018-iubmb_life
5. ramzy et al-2018-iubmb_life
 
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
Predict the therapeutic effect of HDAC inhibitor panobinostat on leukemia by ...
 
Detection of genetically modified soya, maize, and rice in vegetarian and hea...
Detection of genetically modified soya, maize, and rice in vegetarian and hea...Detection of genetically modified soya, maize, and rice in vegetarian and hea...
Detection of genetically modified soya, maize, and rice in vegetarian and hea...
 
Celltrion Healthcare Pipeline
Celltrion Healthcare PipelineCelltrion Healthcare Pipeline
Celltrion Healthcare Pipeline
 
Va sposter ricky_v9_11
Va sposter ricky_v9_11Va sposter ricky_v9_11
Va sposter ricky_v9_11
 

Similaire à PCR detection of virulence factors in Escherichia coli-Tripoli-Libya

Banff 2011 liver transplant pathology summary session
Banff 2011 liver transplant pathology summary sessionBanff 2011 liver transplant pathology summary session
Banff 2011 liver transplant pathology summary sessionKim Solez ,
 
Urinary Tract Infections in Diabetics-Libya
Urinary Tract Infections in Diabetics-LibyaUrinary Tract Infections in Diabetics-Libya
Urinary Tract Infections in Diabetics-Libya-
 
Bacterial infections in cirrhosis
Bacterial infections in cirrhosisBacterial infections in cirrhosis
Bacterial infections in cirrhosisMario Mondelli
 
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...Leonard Davis Institute of Health Economics
 
Overcoming the challenges of molecular diagnostics in government health insti...
Overcoming the challenges of molecular diagnostics in government health insti...Overcoming the challenges of molecular diagnostics in government health insti...
Overcoming the challenges of molecular diagnostics in government health insti...Yakubu Sunday Bot
 
Inflammatory Cytokine, Arsenic and Cancer
Inflammatory Cytokine, Arsenic and Cancer Inflammatory Cytokine, Arsenic and Cancer
Inflammatory Cytokine, Arsenic and Cancer Mezbahul Haque
 
Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy
Analyses of Risk Factors of Diarrhea in Patients with EsophagectomyAnalyses of Risk Factors of Diarrhea in Patients with Esophagectomy
Analyses of Risk Factors of Diarrhea in Patients with Esophagectomysemualkaira
 
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!National Ovarian Cancer Coalition
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...Cytel USA
 
SC CTSI Research Drives Global Health Policy
SC CTSI Research Drives Global Health PolicySC CTSI Research Drives Global Health Policy
SC CTSI Research Drives Global Health PolicySC CTSI at USC and CHLA
 
20180925 nutritionmeeting almere_lecture2
20180925 nutritionmeeting almere_lecture220180925 nutritionmeeting almere_lecture2
20180925 nutritionmeeting almere_lecture2yakult1
 
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicine
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicineDr. Timothy Bowen (Cardiff University) - Data-driven systems medicine
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicinemntbs1
 
HCV infection associated hepatocellular carcinoma
HCV infection associated hepatocellular carcinoma HCV infection associated hepatocellular carcinoma
HCV infection associated hepatocellular carcinoma Dariyus Kabraji
 
Ahmad yusuf chosen
Ahmad yusuf chosenAhmad yusuf chosen
Ahmad yusuf chosenAhmad Badawy
 
Information for doctors
Information for doctorsInformation for doctors
Information for doctorsCereal Inc.
 

Similaire à PCR detection of virulence factors in Escherichia coli-Tripoli-Libya (20)

Toxicité hépatique de l'immunothérapie Eleonora De martin.pdf
Toxicité hépatique de l'immunothérapie Eleonora De martin.pdfToxicité hépatique de l'immunothérapie Eleonora De martin.pdf
Toxicité hépatique de l'immunothérapie Eleonora De martin.pdf
 
Banff 2011 liver transplant pathology summary session
Banff 2011 liver transplant pathology summary sessionBanff 2011 liver transplant pathology summary session
Banff 2011 liver transplant pathology summary session
 
Urinary Tract Infections in Diabetics-Libya
Urinary Tract Infections in Diabetics-LibyaUrinary Tract Infections in Diabetics-Libya
Urinary Tract Infections in Diabetics-Libya
 
Bacterial infections in cirrhosis
Bacterial infections in cirrhosisBacterial infections in cirrhosis
Bacterial infections in cirrhosis
 
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...
Risk Factors for Fluoroquinolone Resistance in Nosocomial Urinary Tract Infec...
 
Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evi...
Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evi...Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evi...
Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evi...
 
Ulcerative collitis
Ulcerative collitisUlcerative collitis
Ulcerative collitis
 
Overcoming the challenges of molecular diagnostics in government health insti...
Overcoming the challenges of molecular diagnostics in government health insti...Overcoming the challenges of molecular diagnostics in government health insti...
Overcoming the challenges of molecular diagnostics in government health insti...
 
Inflammatory Cytokine, Arsenic and Cancer
Inflammatory Cytokine, Arsenic and Cancer Inflammatory Cytokine, Arsenic and Cancer
Inflammatory Cytokine, Arsenic and Cancer
 
Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy
Analyses of Risk Factors of Diarrhea in Patients with EsophagectomyAnalyses of Risk Factors of Diarrhea in Patients with Esophagectomy
Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy
 
2010Ketorolac
2010Ketorolac2010Ketorolac
2010Ketorolac
 
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...
 
SC CTSI Research Drives Global Health Policy
SC CTSI Research Drives Global Health PolicySC CTSI Research Drives Global Health Policy
SC CTSI Research Drives Global Health Policy
 
20180925 nutritionmeeting almere_lecture2
20180925 nutritionmeeting almere_lecture220180925 nutritionmeeting almere_lecture2
20180925 nutritionmeeting almere_lecture2
 
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicine
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicineDr. Timothy Bowen (Cardiff University) - Data-driven systems medicine
Dr. Timothy Bowen (Cardiff University) - Data-driven systems medicine
 
HCV infection associated hepatocellular carcinoma
HCV infection associated hepatocellular carcinoma HCV infection associated hepatocellular carcinoma
HCV infection associated hepatocellular carcinoma
 
New spleen by alajrawee
New spleen by alajraweeNew spleen by alajrawee
New spleen by alajrawee
 
Ahmad yusuf chosen
Ahmad yusuf chosenAhmad yusuf chosen
Ahmad yusuf chosen
 
Information for doctors
Information for doctorsInformation for doctors
Information for doctors
 

Plus de -

Ghenghesh-CV
Ghenghesh-CVGhenghesh-CV
Ghenghesh-CV-
 
Waterborne Pathogens in Developing Countries
Waterborne Pathogens in Developing CountriesWaterborne Pathogens in Developing Countries
Waterborne Pathogens in Developing Countries-
 
Urinary Tract Infection in Diabetic Patients-Libya
Urinary Tract Infection in Diabetic Patients-LibyaUrinary Tract Infection in Diabetic Patients-Libya
Urinary Tract Infection in Diabetic Patients-Libya-
 
Spread of antibiotic resistant pathogenic bacteria in the hospital-Libya
Spread of antibiotic resistant pathogenic bacteria in the hospital-LibyaSpread of antibiotic resistant pathogenic bacteria in the hospital-Libya
Spread of antibiotic resistant pathogenic bacteria in the hospital-Libya-
 
Spread of antibiotic resistant bacteria-Libya
Spread of antibiotic resistant bacteria-LibyaSpread of antibiotic resistant bacteria-Libya
Spread of antibiotic resistant bacteria-Libya-
 
Salmonella in Zliten-Libya
Salmonella in Zliten-LibyaSalmonella in Zliten-Libya
Salmonella in Zliten-Libya-
 
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-LibyaRent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya-
 
Protecting the healthcare worker-Arabic
Protecting the healthcare worker-ArabicProtecting the healthcare worker-Arabic
Protecting the healthcare worker-Arabic-
 
Protecting the healthcare worker from bloodborne infections
Protecting the healthcare worker from bloodborne infectionsProtecting the healthcare worker from bloodborne infections
Protecting the healthcare worker from bloodborne infections-
 
Protecting the family from infectious diseases-Arabic
Protecting the family from infectious diseases-ArabicProtecting the family from infectious diseases-Arabic
Protecting the family from infectious diseases-Arabic-
 
New Emerging Enteric Pathogens-Aeromonas as a Model
New Emerging Enteric Pathogens-Aeromonas as a ModelNew Emerging Enteric Pathogens-Aeromonas as a Model
New Emerging Enteric Pathogens-Aeromonas as a Model-
 
Medical education in Libya-Arabic
Medical education in Libya-ArabicMedical education in Libya-Arabic
Medical education in Libya-Arabic-
 
Maternal transmission of HBV-Libya
Maternal transmission of HBV-LibyaMaternal transmission of HBV-Libya
Maternal transmission of HBV-Libya-
 
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...Ice cream as a possible method of spreading antimicrobial resistant pathogeni...
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...-
 
Foodborne illnesses in developing countries
Foodborne illnesses in developing countriesFoodborne illnesses in developing countries
Foodborne illnesses in developing countries-
 
Enteric viruses-Libya
Enteric viruses-LibyaEnteric viruses-Libya
Enteric viruses-Libya-
 
Enteric pathogens-Tripoli-Libya
Enteric pathogens-Tripoli-LibyaEnteric pathogens-Tripoli-Libya
Enteric pathogens-Tripoli-Libya-
 
Diarrhea in Libyan children presentation
Diarrhea in Libyan children presentationDiarrhea in Libyan children presentation
Diarrhea in Libyan children presentation-
 
Classic and new emerging enteric pathogens-Tripoli-Libya
Classic and new emerging enteric pathogens-Tripoli-LibyaClassic and new emerging enteric pathogens-Tripoli-Libya
Classic and new emerging enteric pathogens-Tripoli-Libya-
 
Can coins and paper money transmit Bacillus anthracis
Can coins and paper money transmit Bacillus anthracisCan coins and paper money transmit Bacillus anthracis
Can coins and paper money transmit Bacillus anthracis-
 

Plus de - (20)

Ghenghesh-CV
Ghenghesh-CVGhenghesh-CV
Ghenghesh-CV
 
Waterborne Pathogens in Developing Countries
Waterborne Pathogens in Developing CountriesWaterborne Pathogens in Developing Countries
Waterborne Pathogens in Developing Countries
 
Urinary Tract Infection in Diabetic Patients-Libya
Urinary Tract Infection in Diabetic Patients-LibyaUrinary Tract Infection in Diabetic Patients-Libya
Urinary Tract Infection in Diabetic Patients-Libya
 
Spread of antibiotic resistant pathogenic bacteria in the hospital-Libya
Spread of antibiotic resistant pathogenic bacteria in the hospital-LibyaSpread of antibiotic resistant pathogenic bacteria in the hospital-Libya
Spread of antibiotic resistant pathogenic bacteria in the hospital-Libya
 
Spread of antibiotic resistant bacteria-Libya
Spread of antibiotic resistant bacteria-LibyaSpread of antibiotic resistant bacteria-Libya
Spread of antibiotic resistant bacteria-Libya
 
Salmonella in Zliten-Libya
Salmonella in Zliten-LibyaSalmonella in Zliten-Libya
Salmonella in Zliten-Libya
 
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-LibyaRent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya
Rent a Car and/or DVD and Get Antimicrobial Resistant Bacteria for Free-Libya
 
Protecting the healthcare worker-Arabic
Protecting the healthcare worker-ArabicProtecting the healthcare worker-Arabic
Protecting the healthcare worker-Arabic
 
Protecting the healthcare worker from bloodborne infections
Protecting the healthcare worker from bloodborne infectionsProtecting the healthcare worker from bloodborne infections
Protecting the healthcare worker from bloodborne infections
 
Protecting the family from infectious diseases-Arabic
Protecting the family from infectious diseases-ArabicProtecting the family from infectious diseases-Arabic
Protecting the family from infectious diseases-Arabic
 
New Emerging Enteric Pathogens-Aeromonas as a Model
New Emerging Enteric Pathogens-Aeromonas as a ModelNew Emerging Enteric Pathogens-Aeromonas as a Model
New Emerging Enteric Pathogens-Aeromonas as a Model
 
Medical education in Libya-Arabic
Medical education in Libya-ArabicMedical education in Libya-Arabic
Medical education in Libya-Arabic
 
Maternal transmission of HBV-Libya
Maternal transmission of HBV-LibyaMaternal transmission of HBV-Libya
Maternal transmission of HBV-Libya
 
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...Ice cream as a possible method of spreading antimicrobial resistant pathogeni...
Ice cream as a possible method of spreading antimicrobial resistant pathogeni...
 
Foodborne illnesses in developing countries
Foodborne illnesses in developing countriesFoodborne illnesses in developing countries
Foodborne illnesses in developing countries
 
Enteric viruses-Libya
Enteric viruses-LibyaEnteric viruses-Libya
Enteric viruses-Libya
 
Enteric pathogens-Tripoli-Libya
Enteric pathogens-Tripoli-LibyaEnteric pathogens-Tripoli-Libya
Enteric pathogens-Tripoli-Libya
 
Diarrhea in Libyan children presentation
Diarrhea in Libyan children presentationDiarrhea in Libyan children presentation
Diarrhea in Libyan children presentation
 
Classic and new emerging enteric pathogens-Tripoli-Libya
Classic and new emerging enteric pathogens-Tripoli-LibyaClassic and new emerging enteric pathogens-Tripoli-Libya
Classic and new emerging enteric pathogens-Tripoli-Libya
 
Can coins and paper money transmit Bacillus anthracis
Can coins and paper money transmit Bacillus anthracisCan coins and paper money transmit Bacillus anthracis
Can coins and paper money transmit Bacillus anthracis
 

Dernier

A Beginners Guide to Building a RAG App Using Open Source Milvus
A Beginners Guide to Building a RAG App Using Open Source MilvusA Beginners Guide to Building a RAG App Using Open Source Milvus
A Beginners Guide to Building a RAG App Using Open Source MilvusZilliz
 
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...Zilliz
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProduct Anonymous
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsNanddeep Nachan
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobeapidays
 
GenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdfGenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdflior mazor
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...Martijn de Jong
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...apidays
 
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot Model
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot ModelNavi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot Model
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot ModelDeepika Singh
 
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps ScriptAutomating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Scriptwesley chun
 
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...apidays
 
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbu
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu SubbuApidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbu
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbuapidays
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfsudhanshuwaghmare1
 
Ransomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdfRansomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdfOverkill Security
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingEdi Saputra
 
A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?Igalia
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processorsdebabhi2
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyKhushali Kathiriya
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxRustici Software
 
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt RobisonData Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt RobisonAnna Loughnan Colquhoun
 

Dernier (20)

A Beginners Guide to Building a RAG App Using Open Source Milvus
A Beginners Guide to Building a RAG App Using Open Source MilvusA Beginners Guide to Building a RAG App Using Open Source Milvus
A Beginners Guide to Building a RAG App Using Open Source Milvus
 
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 
GenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdfGenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdf
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
 
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot Model
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot ModelNavi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot Model
Navi Mumbai Call Girls 🥰 8617370543 Service Offer VIP Hot Model
 
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps ScriptAutomating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Script
 
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
 
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbu
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu SubbuApidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbu
Apidays Singapore 2024 - Modernizing Securities Finance by Madhu Subbu
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
Ransomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdfRansomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdf
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
 
A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processors
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
 
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt RobisonData Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt Robison
 

PCR detection of virulence factors in Escherichia coli-Tripoli-Libya

  • 1. PCR Detection of Virulence Factors in Escherichia coli from Diabetic and Non-Diabetic Patients with Urinary Tract Infections in Tripoli-Libya Khalifa Sifaw Ghenghesh, Einass El-Kateb, Nuri Berbash, Rania Abdel-Khalek, Salwa F. Ahmed, John D. Klena Faculty of Medicine, Tripoli University; Faculty of Sciences; Tripoli University, Tripoli, Libya and US Naval Medical Research Unit#3, Cairo, Egypt.
  • 2. Introduction • Uropathogenic Escherichia coli (UPEC) is the most common cause of urinary tract infections (UTIs) in humans. • UPEC colonization of the UT is made possible by several virulence factors (VF): – – – – – fimbrial adhesins >> e.g. type-1 fimbriae >> adherence nonfimbrial adhesins >> adherence sidrophores >> iron-acquisition systems secreted toxins >> hemolysin cytotoxic necrotizing factor 1 >> acts on epithelial or endothelial cells, or monocyte-macrophages via activation of GTP-binding proteins – capsule-forming polysaccharides >> immune evasion
  • 3. Introduction • Phylogenetic groups of E. coli strains: – Groups A and B1 >> commensal strains. – Groups B2 and D >> mainly associated with E. coli strains causing extraintestinal infections. – Most VFs-containing UPECs cluster mainly either in phylogeny group B2 or shared within groups B2 and D • Fluoroquinolones (e.g. ciprofloxacin): – Drugs of choice in empirical treatment of uncomplicated UTI. – Studies have shown that resistance of UPEC to ciprofloxacin and to may be associated with decreased expression or loss of some virulence factors
  • 4. Introduction • In developed countries: – Several investigators have reported that infections including UTIs are more frequently reported among diabetic patients than the general population, while others found no such difference. – Studies have shown that hosts with predisposing factors, such as diabetes, can acquire UTIs caused by less virulent E. coli strains. • In developing countries. – Lack of information on the phylogenetic grouping and virulence factors of UPEC from diabetic and non-diabetic patients.
  • 5. Objectives of the Study • To determine the phylogenetic grouping and the virulence factors of UPEC isolated from diabetic and non-diabetic patients in Tripoli, Libya using PCR techniques.
  • 6. Methods • Using multiplex PCR – 48 E. coli isolates from Libyan patients with UTIs: • 19 from diabetics and 29 from non-diabetics • Examined for the presence of genetic determinants of 19 extraintestinal virulence factors. • The primer pairs for the 19 virulence genes and amplification conditions have been described previously (Johnson & Stell 2000). • Examined for phylogenetic grouping (A, B1, B2, or D) as previously reported (Clermont et al., 2000). • Reactions were performed in a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). • DNA sequencing was used to confirm the identity of amplified PCR products and establish positive controls.
  • 7. PCR detection of virulence genes in UPEC
  • 8. Results • Of the virulence genes examined, 3 or more were found in 37.5% of E. coli studied. • Only genes fimH (coding for type 1 fimbriae) and traT (coding for serum resistance) were both found significantly more common in E. coli from non-diabetic than in diabetic patients (P<0.02, OR=7.88 and P<0.00007, OR=14.38, respectively). • several of the VFs detected in the present study were not reported previously in E. coli isolates from diabetics with UTI and these include fyuA, kpsMT II, and traT.
  • 9. Table 1. Distribution of virulence factors (VF) among uropathogenic Escherichia coli isolated from diabetics and non-diabetics VF No (%) of associated VF Diabetics Non-diabetics (n=19) (n=29) --------------------------------------------------------------------------------------------------------------------------------------papA (P fimbriae) 0 (0.0) 0 (0.0) papC (P fimbriae) 1 (5) 3 (10) papEF (P fimbriae) 1 (5) 3 (10) sfa/focD (Dr family adhesions) 2 (11) 8 (28) focG (F1C fimbriae) 1 (5) 7 (24) afa/draBC (Dr family adhesions) 0 (0.0) 4 (14) bmaE (M fimbirae) 0 (0.0) 0 (0.0) nfaE (Nonfimbrial adhesion-1) 0 (0.0) 0 (0.0) fimH (Type 1 fimbriae) 12 (63) 27 (93)* hylA (hemolysin) 4 (21) 7 (24) fyuA (Yersiniabactin) 12 (63) 11 (38) iutA (Aerobactin) 13 (68) 21 (72) kpsMT II (Capsule synthesis group II) 7 (37) 11 (38) kpsMT III (Capsule synthesis group III) 0 (0.0) 0 (0.0) rfc (O4 LPS) 0 (0.0) 0 (0.0) ibeA (Invasion) 0 (0.0) 1 (4) cvaC (Colicin V) 0 (0.0) 1 (4) traT (Serum resistance) 4 (21) 23 (79)* PAI (Pathogenicity-associated island) 0 (0.0) 2 (7) Multivirulent (>3 genes) 11 (58) 25 (86)*
  • 10. Table 2. Distribution of virulence factors (VF) among uropathogenic Escherichia coli isolated from diabetics and non-diabetics in relation to ciprofloxacin resistance VF No (%) of associated VF Cipro-susceptible Cipro-resistant (n=38) (n=10) ------------------------------------------------------------------------------------------------------------------------------------------papA (P fimbriae) 0 (0.0) 0 (0.0) papC (P fimbriae) 4 (11) 0 (0.0) papEF (P fimbriae) 4 (11) 0 (0.0) sfa/focD (Dr family adhesions) 10 (26) 0 (0.0) focG (F1C fimbriae) 8 (21) 0 (0.0) afa/draBC (Dr family adhesions) 4 (11) 0 (0.0) bmaE (M fimbirae) 0 (0.0) 0 (0.0) nfaE (Nonfimbrial adhesion-1) 0 (0.0) 0 (0.0) fimH (Type 1 fimbriae) 32 (84)* 4 (40) hylA (hemolysin) 11 (29)* 0 (0.0) fyuA (Yersiniabactin) 19 (50) 4 (40) iutA (Aerobactin) 28 (74)* 4 (40) kpsMT II (Capsule synthesis group II) 18 (47)* 0 (0.0) kpsMT III (Capsule synthesis group III) 0 (0.0) 0 (0.0) rfc (O4 LPS) 0 (0.0) 0 (0.0) ibeA (Invasion) 1 (3) 0 (0.0) cvaC (Colicin V) 1 (3) 0 (0.0) traT (Serum resistance) 23 (61) 4 (40) PAI (Pathogenicity-associated island) 1 (3) 1 (10) Multivirulent (>3 genes) 34 (90)* 2 (20)
  • 11. Phylogeny groups among UPEC isolated from diabetics and non-diabetics and in relation to ciprofloxacin resistance Non Phlyogeny Diabetics diabetics Ciprosusceptible Ciproresistant group (n=19) (n=29) (n=38) (n=10) --------------------------------------------------------------------------------------------------------------------- A B1 B2 D 14 (74)1 0 (0.0) 3 (16) 2 (11) 4 (14) 1 (3.4) 8 (28) 16 (55)3 10 (26) 1 (3) 10 (26) 17 (45)4 8 (80)2 0 (0.0) 1 (10) 1 (10)
  • 12. Results • E. coli from diabetics is significantly statistically associated with phylogeny group A than E. coli from non-diabetics (P<0.00003, OR=17.50). • E. coli from non-diabetics is significantly statistically associated with phylogeny group D than E. coli from diabetics (P<0.002, OR=10.46). • Ciprofloxacin-resistant E. coli is significantly statistically associated with phylogeny group A than ciprofloxacin-susceptible E. coli (P<0.002, OR=11.20). • Ciprofloxacin-susceptible E. coli is significantly statistically associated with phylogeny group D than ciprofloxacin-resistant E. coli (P<0.05, OR=7.29).
  • 13. Conclusion • In developing countries, UPEC causing UTIs in diabetics are less virulent than UPEC causing UTIs in non-diabetics which confirms the findings of previously published studies from developed countries. • Studies are needed on the prevalence of VFs and phylogenetic groups in UPEC from diabetic patients in developing areas. • These studies are important in understanding the roles of these factors in causing UTI in diabetics as well as in non-diabetics, which in turn may lead to development of universal vaccines to prevent such infections.